Developer docs
API playgroundTry for free, no card

Search company profiles

Tecnovax

Full company profile

uuid000evh9

Namestring
Tecnovax
Websiteurl
tecnovax.com.ar
Company typeenum
Private
Founded yearint
2003
Descriptiontext

Tecnovax is an Argentine biopharmaceutical company that manufactures biological products for animal health. Founded in 2003 and headquartered in Victoria, Argentina, the company operates in the veterinary biologics segment, which typically includes vaccines and other immunological products for livestock and companion animals. The firm is privately held and has sustained operations for 21 years, currently maintaining a workforce of 101–250 employees. Leadership is founder-led, with Diego La Torre serving as co-founder and CEO, providing strategic continuity since inception.

The company's product portfolio, technology platform, manufacturing footprint, and regulatory registrations are not disclosed in the available source data. The corporate website (tecnovax.com.ar) was inaccessible beyond a loading/verification page during data collection, and no product catalog, technical specifications, patents, certifications, or partnership disclosures were available. This represents a significant data gap for evaluating Tecnovax's competitive positioning within the regional and global animal health biologics market.

Tecnovax's business model is also not disclosed in the source material. There is no public information on pricing, distribution channels, customer segments, geographic markets served, or revenue mechanics. As a manufacturer of regulated veterinary biologicals, the most plausible go-to-market is B2B distribution through veterinary wholesalers, livestock producers, and government animal health programs, but this is an inference rather than a documented fact. Investors seeking to diligence the company should request primary documentation on revenue, product registrations, and export footprint.

Short descriptiontext

Tecnovax is an Argentine biopharmaceutical company founded in 2003 that manufactures biological products for animal health, serving veterinary and livestock markets from Victoria, Argentina. It is a privately held, founder-led firm with 101–250 employees.

Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersVictoria, Argentina
HQ citystring
Victoria
HQ countrystring
Argentina
HQ regionstring
Latin America
Markets served

Serves global market

Keyword5 values
animal health biologics, veterinary vaccines, biological products, veterinary pharmaceuticals, livestock health
Industry2 codes
1Veterinary Vaccines (Biologics)
CodeHLAMAEALPrimaryYes
2Livestock & Production Animal Therapeutics (Rx)
CodeHLAMAEABPrimaryNo
NAICS code1 code
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Veterinary Biologics
Social media profiles1 record
Cost components4 values
Operations, Supply Chain, Personnel, Technology or R&D
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Tecnovax is a biopharmaceutical company that manufactures biological products for animal health. Founded in 2003 and headquartered in Victoria, Argentina, the company develops and produces veterinary biologics aimed at the livestock and animal health sectors.

Differentiator
Functional benefit
Problem solved
Recent move3 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight1 record

Each record includes

Type, Description

Peers10 records
1Zoetis
TypeBroad incumbent
Description

Global leader in animal health medicines and vaccines. Directly comparable as a veterinary biologics manufacturer serving livestock and companion animal markets, though at vastly larger scale and with a broad portfolio.

2Boehringer Ingelheim Animal Health
TypeBroad incumbent
Description

Major multinational animal health division with a strong veterinary vaccines portfolio. Comparable to Tecnovax as a biological products manufacturer for animal health, with broader geographic reach and species coverage.

3MSD Animal Health (Merck Animal Health)
TypeBroad incumbent
Description

Global animal health division of Merck with extensive livestock vaccine and biologic offerings. Direct competitor in the veterinary biologics space across multiple species and geographies.

4Elanco Animal Health
TypeBroad incumbent
Description

Major global animal health company with significant vaccines and therapeutics portfolio. Comparable as a broad-line animal health biologics competitor.

5Biogénesis Bagó
TypeDirect peer
Description

Argentine veterinary biologics manufacturer focused on livestock vaccines, including foot-and-mouth disease. The most direct regional peer to Tecnovax, operating from the same home market with a similar product category and customer base.

6Virbac
TypeBroad incumbent
Description

Global animal health company with vaccines, parasiticides, and specialty products. Comparable to Tecnovax in vaccines/biologics manufacturing scope, though with a broader product mix and global distribution.

7Ceva Santé Animale
TypeBroad incumbent
Description

Multinational animal health company with a meaningful vaccines and biologics portfolio. Comparable as a biological products manufacturer for animal health, with growing emerging market presence.

8Vetoquinol
TypeBroad incumbent
Description

Global veterinary pharmaceuticals and biological products company. Comparable in manufacturing veterinary medicines, with overlap on livestock and companion animal categories.

9Instituto Rosenbusch
TypeRegional player
Description

Argentine veterinary biologics manufacturer focused on livestock vaccines. Closely comparable regional peer operating in the same home geography with a similar product profile.

10Phibro Animal Health
TypeBroad incumbent
Description

Animal health and nutrition company with vaccines and pharmaceutical products for livestock. Comparable as a veterinary biologics and pharmaceutical manufacturer, though with broader nutritional product lines.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights4 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Tecnovax

Veterinary Biologicstecnovax.com.ar

Tecnovax is an Argentine biopharmaceutical company founded in 2003 that manufactures biological products for animal health, serving veterinary and livestock markets from Victoria, Argentina. It is a privately held, founder-led firm with 101–250 employees.

What Tecnovax does

Tecnovax is an Argentine biopharmaceutical company that manufactures biological products for animal health. Founded in 2003 and headquartered in Victoria, Argentina, the company operates in the veterinary biologics segment, which typically includes vaccines and other immunological products for livestock and companion animals. The firm is privately held and has sustained operations for 21 years, currently maintaining a workforce of 101–250 employees. Leadership is founder-led, with Diego La Torre serving as co-founder and CEO, providing strategic continuity since inception.

The company's product portfolio, technology platform, manufacturing footprint, and regulatory registrations are not disclosed in the available source data. The corporate website (tecnovax.com.ar) was inaccessible beyond a loading/verification page during data collection, and no product catalog, technical specifications, patents, certifications, or partnership disclosures were available. This represents a significant data gap for evaluating Tecnovax's competitive positioning within the regional and global animal health biologics market.

Tecnovax's business model is also not disclosed in the source material. There is no public information on pricing, distribution channels, customer segments, geographic markets served, or revenue mechanics. As a manufacturer of regulated veterinary biologicals, the most plausible go-to-market is B2B distribution through veterinary wholesalers, livestock producers, and government animal health programs, but this is an inference rather than a documented fact. Investors seeking to diligence the company should request primary documentation on revenue, product registrations, and export footprint.

Tecnovax firmographics

Firmographics
Name
Tecnovax
Website
https://tecnovax.com.ar
Company type
Private
Founded year
2003
Headcount range
101–250 employees
Short description
Tecnovax is an Argentine biopharmaceutical company founded in 2003 that manufactures biological products for animal health, serving veterinary and livestock markets from Victoria, Argentina. It is a privately held, founder-led firm with 101–250 employees.
Ownership category
akta.pro rank

Tecnovax industry classification

Industry
Product category
Veterinary Biologics
NAICS
Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro primary industry
Veterinary Vaccines (Biologics) (HLAMAEAL)
akta.pro secondary industry
Livestock & Production Animal Therapeutics (Rx) (HLAMAEAB)

Keywords

  • Animal health biologics
  • Veterinary vaccines
  • Biological products
  • Veterinary pharmaceuticals
  • Livestock health

Where Tecnovax is headquartered

Location

Headquarters

HQ city
Victoria
HQ country
Argentina
HQ region
Latin America

Markets served

Tecnovax business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Operations, Supply Chain, Personnel, Technology or R&D

Tecnovax product offering

Product offering

Core offering

Tecnovax is a biopharmaceutical company that manufactures biological products for animal health. Founded in 2003 and headquartered in Victoria, Argentina, the company develops and produces veterinary biologics aimed at the livestock and animal health sectors.

Differentiator

Problem solved

Functional benefit

Companies that use Tecnovax

Customer profile

Ideal customer profiles1 record

Tecnovax technology and API

Technology

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Tecnovax partnerships and signals

Strategic signal

Recent moves3 records

Expansion highlights1 record

Tecnovax competitors and assessment

Company assessment

Broad incumbents

  • Zoetis: Global leader in animal health medicines and vaccines. Directly comparable as a veterinary biologics manufacturer serving livestock and companion animal markets, though at vastly larger scale and with a broad portfolio.
  • Boehringer Ingelheim Animal Health: Major multinational animal health division with a strong veterinary vaccines portfolio. Comparable to Tecnovax as a biological products manufacturer for animal health, with broader geographic reach and species coverage.
  • MSD Animal Health (Merck Animal Health): Global animal health division of Merck with extensive livestock vaccine and biologic offerings. Direct competitor in the veterinary biologics space across multiple species and geographies.
  • Elanco Animal Health: Major global animal health company with significant vaccines and therapeutics portfolio. Comparable as a broad-line animal health biologics competitor.
  • Virbac: Global animal health company with vaccines, parasiticides, and specialty products. Comparable to Tecnovax in vaccines/biologics manufacturing scope, though with a broader product mix and global distribution.
  • Ceva Santé Animale: Multinational animal health company with a meaningful vaccines and biologics portfolio. Comparable as a biological products manufacturer for animal health, with growing emerging market presence.
  • Vetoquinol: Global veterinary pharmaceuticals and biological products company. Comparable in manufacturing veterinary medicines, with overlap on livestock and companion animal categories.
  • Phibro Animal Health: Animal health and nutrition company with vaccines and pharmaceutical products for livestock. Comparable as a veterinary biologics and pharmaceutical manufacturer, though with broader nutritional product lines.

Direct peers

  • Biogénesis Bagó: Argentine veterinary biologics manufacturer focused on livestock vaccines, including foot-and-mouth disease. The most direct regional peer to Tecnovax, operating from the same home market with a similar product category and customer base.

Regional players

  • Instituto Rosenbusch: Argentine veterinary biologics manufacturer focused on livestock vaccines. Closely comparable regional peer operating in the same home geography with a similar product profile.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights4 records

Customer concentration

Tecnovax social profiles

Digital presence

Tecnovax financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Tecnovax leadership team

Management profile

Number of profiles

Profiles1 record

Tecnovax funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Tecnovax M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Tecnovax

What does Tecnovax do?

Tecnovax is a biopharmaceutical company that manufactures biological products for animal health. Founded in 2003 and headquartered in Victoria, Argentina, the company develops and produces veterinary biologics aimed at the livestock and animal health sectors.

When was Tecnovax founded?

Tecnovax was founded in 2003. It employs 101 to 250 people.

Where is Tecnovax based?

Tecnovax is headquartered in Victoria, Argentina, in the Latin America region.

Who are Tecnovax's main competitors?

Broad incumbents on record are Zoetis, Boehringer Ingelheim Animal Health, MSD Animal Health (Merck Animal Health), Elanco Animal Health, Virbac, Ceva Santé Animale, Vetoquinol and Phibro Animal Health. Biogénesis Bagó is listed as a direct peer. Instituto Rosenbusch is listed as a regional player.

Does Tecnovax have an API?

No public API is recorded for Tecnovax.

What industry is Tecnovax in?

Tecnovax's product category is Veterinary Biologics. Its primary akta.pro industry code is HLAMAEAL, Veterinary Vaccines (Biologics), with a secondary code of HLAMAEAB, Livestock & Production Animal Therapeutics (Rx). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
El CronistaLa derrota de Sturzenegger: el mercado que no logra desregularArgentina's Minister of Deregulation Federico Sturzenegger has failed to introduce competition into the foot-and-mouth disease vaccine market, which is worth over $150 million and has been dominated for decades by Biogénesis Bagó. Despite regulatory changes intended to allow competitor Tecnovax to enter the market, a key obstacle remains: Biogénesis Bagó's vaccine requires one dose per campaign while Tecnovax's was approved only for semi-annual use, making it uncompetitive. The situation has been compounded by Biogénesis Bagó's influence over the regulatory body Senasa, including a convenant arrangement under which the company supports the agency's technicians and facilities.El CronistaUna biotecnológica “de nicho” se financió con ON para ganar escala en vacunas y exportarTecnovax, an Argentine biotech company specializing in veterinary vaccines and biopharmaceuticals for animal health, raised $5 million through a bond issuance (Obligaciones Negociables) to finance construction of a new production plant in Mercedes, Buenos Aires. The new facility will increase the company's biopharmaceutical capacity and support its export expansion strategy, particularly targeting the Chilean salmon market. Diego La Torre, the company's CEO, stated the investment is part of a broader global growth plan focused on developing new products and expanding commercial presence in new markets.LA NACIONUna empresa de capitales argentinos consiguió US$5 millones y acelera la construcción de una nueva planta industrialThe Argentine animal health company Tecnovax successfully raised US$5 million through a new issuance of Negotiable Obligations, with the placement attracting strong investor demand and favorable financing conditions. The funds will primarily finance the construction of a new industrial plant to expand the company's biopharmaceutical capacity and refinance short-term financial liabilities. The company noted this issuance reflects positive market recognition of its credit profile and track record of on-time repayments, as it pursues a global growth strategy and international market expansion.